Amivantamab, a bispecific monoclonal antibody targeting EGFR and MET, received its first FDA approval for the treatment of patients with NSCLC harboring EGFR exon 20 insertion mutations on 21 May 2021 [261]. Here, EGFR is linked to non-small cell lung carcinoma.